Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Neurology® 2019;92:112. doi:10.1212/WNL.0000000000006722

In the Special Article “Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology” by A. Rae-Grant et al.,¹ there are errors on page 780 of the full article. The Starting: Recommendation 12 Rationale should state “With teriflunomide treatment, there may be a risk of teratogenicity from male *seminal fluid*, which could last for 2 years after treatment cessation if the patient is not treated with *adsorption* therapy” rather than “With teriflunomide treatment, there may be a risk of teratogenicity from male sperm, which could last for 2 years after treatment cessation if the patient is not treated with chelation therapy” as originally published. The authors regret the errors.

Reference

1. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology* 2018;90:777–788.

Neurology®

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Neurology 2019;92;112

DOI 10.1212/WNL.0000000000006722

This information is current as of January 7, 2019

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/92/2/112.full
References	This article cites 1 articles, 1 of which you can access for free at: http://n.neurology.org/content/92/2/112.full#ref-list-1
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2019 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.